Coherus Biosciences, Inc.

Servicenow, Inc.

Shire Viropharma Incorporated

Kiniksa Pharmaceuticals, Ltd.

Levo Therapeutics, Inc.

Viropharma Biologics LLC

Grifols Therapeutics Inc.

Tracon Pharmaceuticals, Inc.

Airway Therapeutics, Inc.

Orbid Limited

Itrace Limited

Mark Cornell Manning

Robert W Payne

Brian P Murphy

Ryan Erik Holcomb

Stephen Ruddy

Jun Liu

Kurt Joseph Zettel, Ii

Richard Kenneth Reybok

Jeffrey Rhines

Scott Lewis

Henry Geddes

Volodymyr Osypov

Sean Brady

Andreas Seip Haugsnes

Zahra Shahrokh

Christopher Bryant

Isaias Prado

Dave Nichols

Wenchang Ji

Patrick Daniel Begley

Phillip M Levesque

John Ogez

Jianxin Guo

Charles P Theuer

Jan Susan Rosenbaum

Sekhar Kanapuram

Douglas Farrar

Suzanne Pritchett Benedict

Anthony Klos

Sara Cotter

Deborah Barnette

Derrick Spencer Katayama

Ryan R Manning

Joseph William Cormier

Alan Herman

Philip M Levesque

Sharon Real

Andreis Seip Haugsnes

Bret Coldren

Cynthia Gallagher

Steven Ruddy

Brian Murphy

Some embodiments of the methods and compositions provided herein include identifying and/or quantifying oligomeric species of surfactant protein-D (SP-D). Some embodiments include performing an asymmetric flow field-flow fractionation with multi-angle laser light scattering (AF4-MALLS) analysis on the SP-D.

Systems and methods for characterizing surfactant protein D (SP-D) oligomers

A two-dimensional marker for marking an object comprises a plurality of line segments each extending between a first end point and a second end point thereof, wherein at least one of the line segments comprises a shape of at least one period of a periodic waveform.

Method of marking an object, method for generating a marker, method for generating a marker code, and method for authenticating an object

This disclosure provides techniques for pooling and searching network security events reported by multiple sources. As information representing a security event is received from one source, it is searched against a central or distributed database representing events reported from multiple, diverse sources (e.g., different client networks). Either the search or correlated results can be filtered and/or routed according at least one characteristic associated with the networks, for example, to limit correlation to events reported by what are presumed to be similarly situated networks. The disclosed techniques facilitate faster identification of high-relevancy security event information, and thereby help facilitate faster threat identification and mitigation. Various techniques can be implemented as standalone software (e.g., for use by a private network) or for a central pooling and/or query service. This disclosure also provides different examples of actions that can be taken in response to search results.

Techniques for sharing network security event information

A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of aflibercept, wherein the formulation is free of organic co-solvent and/or free of buffer; methods for making such a formulation; and methods of using such a formulation.

Stable aqueous formulations of aflibercept

The present invention is directed to compositions and methods for stabilizing a protein without a surfactant. The present invention is further directed to compositions comprising a protein and at least one excipient selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, low molecular weight aliphatic polyacids, zwitterions, phospholipids, cyclodextrins, polyethylene glycols, gelatins, urea, ethanol, glycerin, dextran, xanthan gum, 2-(2-ethoxyethoxy)ethanol, hydroxypropyl cellulose, propylene glycol, a short-chain organic acid, deoxycholate, sodium nitrate, sodium sulfate, proline and lysine.

Stable protein compositions and methods of their use

The present invention is directed to methods for filling a container wherein the filled container has no headspace. The present invention is further directed to methods for stabilizing an aqueous drug substance solution by filling a container with the aqueous drug substance solution wherein the filled container has no headspace. The present invention is further directed to methods for detecting headspace in a container.

Method of filling a container with no headspace

Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.

C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficiency

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Carbetocin drug product and process for preparing same

The present invention relates to aqueous pharmaceutical compositions comprising a high concentration (i.e., greater than 50 milligrams per milliliter) of adalimumab (including antibody proteins considered or intended as 'biosimilar' or 'bio-better' variants of commercially available adalimumab) suitable for long-term storage, and methods of manufacture of the compositions; methods of their administration; and articles containing the same.

High concentration formulations of adalimumab

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Pr&#xe4;der-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

Agitation process for preparing a carbetocin drug product

A two-dimensional marker () for marking an object comprises a plurality of line segments () each extending between a first end point and a second end point thereof, wherein at least one of the line segments comprises a shape of at least one period of a periodic waveform.

Two-dimensional marker for marking an object, method and system for generating the marker, method and system for generating a marker code, and method and system for authenticating an object

The present invention provides, among other things, stable formulations comprising an anti-oncostatin M receptor (OSMR) antibody and having a pH ranging from approximately 6.0-7.6, wherein less than approximately 5% of the anti-OSMR antibody exists as high molecular weight (HMW) species in the formulation.

Stable anti-OSMR antibody formulation

Growing community of inventors

Johnstown, CO, United States of America

Mark Cornell Manning